Treatment of poor prognosis metastatic teratoma
| ISRCTN | ISRCTN14535482 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14535482 |
| Secondary identifying numbers | TE13 |
- Submission date
- 28/02/2001
- Registration date
- 28/02/2001
- Last edited
- 29/10/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Miss Sharon Naylor
Scientific
Scientific
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
| abc@email.com |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Not Specified |
| Scientific title | Treatment of poor prognosis metastatic teratoma |
| Study objectives | Determine whether treatment with the intensive regimen BOP/VIP-B is more effective than BEP/P. To determine the effect of G-CSF on the proportion of patients receiving full dose intensity of combination chemotherapy with either regimen. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Metastatic teratoma |
| Intervention | Arm 1 - Without granulocyte colony stimulating factor (G-CSF), BEP/EP. Arm 2 - Without G-CSF, BOP/VIP-B. Arm 3 - With G-CSF, BEP/EP. Arm 4 - With G-CSF, BOP/VIP-B. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Several |
| Primary outcome measure | Progression-free survival |
| Secondary outcome measures | Response rate, overall survival |
| Overall study start date | 01/02/1991 |
| Completion date | 31/12/1994 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 154 |
| Key inclusion criteria | Histologically proven non-seminomatous germ cell tumour |
| Key exclusion criteria | Previous radiotherapy or chemotherapy |
| Date of first enrolment | 01/02/1991 |
| Date of final enrolment | 31/12/1994 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
Medical Research Council (MRC) (UK)
Research council
Research council
20 Park Crescent
London
W1B 1AL
United Kingdom
| Phone | +44 (0)20 7636 5422 |
|---|---|
| clinical.trial@headoffice.mrc.ac.uk | |
| Website | http://www.mrc.ac.uk |
Funders
Funder type
Research council
Medical Research Council (MRC) (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
29/10/2019: No publications found. All search options exhausted.
